<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00921895</url>
  </required_header>
  <id_info>
    <org_study_id>200-003</org_study_id>
    <nct_id>NCT00921895</nct_id>
    <nct_alias>NCT00799318</nct_alias>
  </id_info>
  <brief_title>A Comparison of the RPS Adeno Detector IV to Viral Cell Culture at Detecting Adenoviral Conjunctivitis</brief_title>
  <official_title>A Comparison of the Sensitivity and Specificity of the RPS Adeno Detector IVâ„¢ at Detecting the Presence of Adenovirus to Viral Cell Culture.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rapid Pathogen Screening</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rapid Pathogen Screening</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To engage in a multi-center, prospective, masked clinical trial to investigate a
      non-invasive, rapid diagnostic test, the RPS Adeno Detector IV's ability to detect the
      presence of the adenovirus (ADV) antigen in cases of acute conjunctivitis by comparing it to
      cell culture with confirmatory immunofluorescence (CC-IFA). The polymerase chain reaction
      (PCR) will be used as a referee for discrepant cases.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The RPS Adeno Detector IV will show substantial equivalence to cell culture for diagnosing
      adenoviral conjunctivitis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity and Specificity of RPS Adeno Detector IV Compared to Cell Culture.</measure>
    <time_frame>15 minutes</time_frame>
    <description>Sensitivity is proportion of true positive cases compared to cell culture. Specificity is the proportion of true negative cases compared to cell culture.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">128</enrollment>
  <condition>Conjunctivitis</condition>
  <arm_group>
    <arm_group_label>Device Testing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with conjunctivitis will be tested with the RPS Adeno Detector IV</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RPS Adeno Detector IV</intervention_name>
    <description>One time test with the RPS Adeno Detector IV</description>
    <arm_group_label>Device Testing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A total of 150 patients will be enrolled and who present prospectively to either a
             private practice or academic center with a presumed diagnosis of acute viral
             conjunctivitis while an internal review board (IRB) approved ophthalmologist is
             available and determined by the ophthalmologist to have met the following criteria for
             the clinical diagnosis of acute viral conjunctivitis will be included in the study.

          -  Criteria for clinical diagnosis of viral conjunctivitis. Requires that patients are at
             least 1 month old and present within 7 days of developing a red eye with at least 1
             criteria from each of the 3 categories below:

        I History: 1) Spread from 1 eye to the other several days later, 2) a recent history of an
        upper respiratory infection (URI)

        II Signs: 1) presence of follicles, 2) presence of a preauricular node

        III Symptoms: 1) watery - purulent discharge, 2) eyelash matting, 3) itching, or 4) foreign
        body sensation

        Exclusion Criteria:

          -  Patients with allergy to corn starch, talcum powder, or dacron will be excluded.

          -  Patients with a corneal ulcer or history of recent trauma will also be excluded.

          -  Any patients who are using any topical ointment (including OTC artificial tear
             ointments) in the last 72 hours should be excluded.

          -  Patients using other topical ophthalmic medications (i.e. antibiotics) must allow 60
             minutes prior to device application following any topical ophthalmic drops.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shachar Tauber, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St John's Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jodi Luchs, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>South Shore Eye Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William Trattler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center For Excellence In Eye Care</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Boland, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northeastern Eye Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael DellaVecchia, MD/PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wills Eye Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Murray Friedberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Manatee Eye Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chris Starr, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marguerite McDonald, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ophthalmic Consultants of Long Island</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Manatee Eye Clinic</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center For Excellence in Eye Care</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St John's Clinic</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ophthalmic Consultants of Long Island</name>
      <address>
        <city>Lynbrook</city>
        <state>New York</state>
        <zip>11563</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill-Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Shore Eye Care</name>
      <address>
        <city>Wantagh</city>
        <state>New York</state>
        <zip>11793</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wills Eye Institute</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northeastern Eye Institute</name>
      <address>
        <city>Scranton</city>
        <state>Pennsylvania</state>
        <zip>18503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 14, 2009</study_first_submitted>
  <study_first_submitted_qc>June 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2009</study_first_posted>
  <results_first_submitted>August 22, 2012</results_first_submitted>
  <results_first_submitted_qc>August 22, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 24, 2012</results_first_posted>
  <last_update_submitted>October 26, 2015</last_update_submitted>
  <last_update_submitted_qc>October 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pink Eye,</keyword>
  <keyword>Viral conjunctivitis</keyword>
  <keyword>Adenoviral conjunctivitis</keyword>
  <keyword>Keratoconjunctivitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The recruitment period was June 2009 - May 2011. The study was performed at private ophthalmology practices and academic centers.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Device Testing</title>
          <description>Patients with conjunctivitis will be tested with the RPS Adeno Detector IV</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="128"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="128"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Device Testing</title>
          <description>Patients with conjunctivitis will be tested with the RPS Adeno Detector IV</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="128"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43" lower_limit="5" upper_limit="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Sensitivity and Specificity of RPS Adeno Detector IV Compared to Cell Culture.</title>
        <description>Sensitivity is proportion of true positive cases compared to cell culture. Specificity is the proportion of true negative cases compared to cell culture.</description>
        <time_frame>15 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RPS Adeno Detector IV (Sensitivity)</title>
            <description>Looking for the number of true positives as compared to cell culture.</description>
          </group>
          <group group_id="O2">
            <title>RPS Adeno Detector IV (Specificity)</title>
            <description>Looking for the number of true negatives as compared to cell culture.</description>
          </group>
        </group_list>
        <measure>
          <title>Sensitivity and Specificity of RPS Adeno Detector IV Compared to Cell Culture.</title>
          <description>Sensitivity is proportion of true positive cases compared to cell culture. Specificity is the proportion of true negative cases compared to cell culture.</description>
          <units>percentage of cases</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90" lower_limit="74.2" upper_limit="98.0"/>
                    <measurement group_id="O2" value="96" lower_limit="89.8" upper_limit="98.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Device Testing</title>
          <description>Patients with conjunctivitis will be tested with the RPS Adeno Detector IV</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Results to be published or presented shall be submitted to RPS for review and comment at least 30 days prior to submission for publication or presentation. Institution and/or PI may publish or present the results and data from the Institution's site individually (i) 12 months after conclusion, abandonment or termination of study at all sites, or (ii) after RPS confirms there will be no multicenter study publication, whichever occurs first.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Robert Sambusky, MD</name_or_title>
      <organization>Rapid Pathogen Screening, Inc.</organization>
      <phone>941-556-1853</phone>
      <email>sambursky@rpsdetectors.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

